Could a triple therapy help rectal cancer patients avoid a colostomy bag?

NCT ID NCT07397442

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests a new combination of short-course radiation, two immunotherapy drugs (Qibei'an and Camrelizumab), and chemotherapy (XELOX) in 19 people with locally advanced rectal cancer. The goal is to see if this approach can make the tumor disappear completely, allowing patients to avoid permanent colostomy. All participants receive the experimental treatment, and they will be followed for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Short-course radiotherapy, Qibei'an (iparolizumab-tovorilimab), Camrelizumab, and XELOX chemotherapy (oxaliplatin + capecitabine)
What this could lead to
If successful, this combination could help more people with rectal cancer avoid permanent colostomy bags by making the tumor disappear completely before surgery.
What could go wrong
This is a very early, small study with only 19 people, so results may not apply to everyone. The combination of radiation, chemo, and immunotherapy may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER STAGE II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100050, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.